The aim is to evaluate the use and effects of CKM therapy in individuals with Type 1 diabetes and chronic kidney disease.
Observed patients with Type 1 diabetes and chronic kidney disease
Analyzed the association of CKM therapy with UACR reduction
Investigated safety profiles
CKM therapy was frequently utilized among patients with Type 1 diabetes and CKD
Associated with a reduction in UACR
Considered safe, indicating potential for further clinical trials
Abstract
CKM therapy was frequently used in patients with Type 1 diabetes and CKD, associated with UACR reduction and safe. These clinically relevant data warrant confirmation in randomised clinical trials.